Focus on Dialysis Mosby, chapter 47 S. Buckley, RN, MS Fall, N246 Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc.

Download Report

Transcript Focus on Dialysis Mosby, chapter 47 S. Buckley, RN, MS Fall, N246 Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc.

Focus on Dialysis

Mosby, chapter 47 S. Buckley, RN, MS Fall, N246

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Kidneys

• • •

Function: principal organs of the urinary system. Primary functions are: 1. regulate the volume and composition of extracellular fluid (ECF) 2. excrete waste products from the body

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Additional functions of kidneys

• • • •

Control BP Produce erythropoietin (stimulates production of RBC’s) Activate vitamin D Regulate acid base balance (renin, angiotensen)

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Why the need for dialysis?

Renal failure-complete or partial impairment of kidney function resulting in an inability to excrete metabolic waste products and fluid, as well as causing functional disturbances of all body systems.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Renal failure

• • •

Acute (ARF)-syndrome characerized by a rapid loss of renal function with progressive azotemia.

Mortality rate for intrarenal ARF is ~50% Chronic (CKD)-usually develops slowly over months to years and necessitates the initiation of dialysis or transplantation.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

terms related to the phases of renal failure

• •

Oliguria-diminished urine output related to inadequate perfusion of kidney. U/O <400ml/day.

Uremia-condition in which renal function declines and symptoms develop. Accumulation of metabolic byproducts that are normally excreted by the kidneys

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

terms

• • • • • •

Anuria-absence of urine formation.

Polyuria-large volumes of urine Hematuria-blood in urine Anemia- hemoglobin (Hgb) <13 g/dl, (Occurs in most patients with CKD) Pruritis-itching or burning skin.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Urine formation

Outcome of multistep process of filtration, reabsorption, secretion, and excretion of water, electrolytes, and metabolic waste products. Urine is result of process, but primary function is to filter the blood and maintain the body’s internal homeostasis.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Glomerular filtration

• •

Urine formation begins at the glomerulus, where blood is filtered.

Glomerulus is semipermeable membrane the allows filtration. The hydrostatic pressure of the blood within the glomerular capillaries causes a portion of the blood to be filtered across the membrane.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Glomerular filtration rate

• •

The amount of blood filtered by the glomeruli in a given time is termed the glomerular filtration rate (GFR).

Normal GFR=125ml/min.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Creatinine clearance

• • •

Most common indicator used to analyze urinary system disorders (creatinine clearance).

Creatinine is a waste product produced by muscle breakdown. Urinary excretion is a measure of the amount of active muscle tissue in the body. Value range-85-135ml/min.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

BUN and creatinine

• •

BUN-blood urea nitrogen-commonly used test. Concentration of urea in blood, breakdown of amino acids (regulated by rate of kidney excretion) Normal finding-10-30mg/dl

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Chronic and acute kidney disease

• •

Occurs when kidneys are no longer able to clean toxins and waste from blood.

Symptoms of failure: changes in urination, edema, weakness, fatigue, ammonia breath, flank pain, itching, n & V.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Prevalence of CKD

• • • • • •

16.8% of U.S. population (CDC, 2004) Greater among people with diabetes (40.2%) Non-Hispanic African Americans (19.9%) Mexican Americans (18.7%.) Native Americans (3x white pop, ~45%!!!).

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

The average annual incidence rate of dialysis was 12 times greater in persons with diabetes (130 per 100 000) vs without diabetes (11 per 100 000). By 1999–2000, diabetic patients comprised 51% of the incident dialysis population. The average annual prevalence rate was 10 times greater in the diabetic cohort. Patients with diabetes had more co morbidities at the start of dialysis and poorer 3 year survival (55 vs 68%; P<0.0001).

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Dialysis

• • •

Movement of fluid/molecules across a semipermeable membrane from one compartment to another Used to correct fluid/electrolyte imbalances and to remove waste products in renal failure Treat drug overdoses

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Dialysis (Cont’d)

Two methods of dialysis available

Peritoneal dialysis (PD)

Hemodialysis (HD)

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Dialysis (Cont’d)

• •

Begun when patient’s uremia can no longer be adequately managed conservatively Initiated when GFR (or creatinine clearance) <15 ml/min

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Dialysis (Cont’d)

Certain uremic complications also indicate a need

Encephalopathy, pericarditis

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

General Principles of Dialysis

Diffusion

Movement of solutes from an area of greater concentration to an area of lesser concentration

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

General Principles of Dialysis (Cont’d)

Osmosis

Movement of fluid from an area of lesser concentration to an area of greater concentration of solutes

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

General Principles of Dialysis (Cont’d)

Ultrafiltration

Water and fluid removal

Results when there is an osmotic gradient across the membrane

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Osmosis and Diffusion Across Semipermeable Membrane

Fig. 47-7

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis

• • •

Peritoneal access is obtained by inserting a catheter through the anterior wall Technique for catheter placement varies Usually done via surgery

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis (Cont’d)

• • • •

After catheter inserted, skin is cleaned with antiseptic solution and sterile dressing applied Connected to sterile tubing system Secured to abdomen with tape Catheter irrigated immediately

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis (Cont’d)

• • •

Waiting period of 7 to 14 days preferable 2 to 4 weeks after implantation, exit site should be clean, dry, and free of redness/tenderness Once site is healed, patient may shower and pat dry

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Tenckhoff Catheter

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-8

Fig. 47-9 A-C and Fig. 47-10

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis

Dialysis Solutions and Cycles

• • •

Available in 1- or 2-L plastic bags with glucose concentrations of 1.5%, 2.5%, and 4.25% Electrolyte composition similar to plasma Solution warmed to body temperature

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis Dialysis Solutions and Cycles (Cont’d)

Three phases of PD cycle

Called an exchange

• •

Inflow (fill) Dwell (equilibration)

Drain

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis Dialysis Solutions and Cycles (Cont’d)

Inflow

Prescribed amount of solution infused through established catheter over

about 10 minutes After solution infused, inflow clamp closed to prevent air from entering tubing

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis Dialysis Solutions and Cycles (Cont’d)

Dwell

Diffusion and osmosis occur between patient’s blood and peritoneal cavity

Duration of time varies depending on method

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-12

Peritoneal Dialysis Dialysis Solutions and Cycles (Cont’d)

Drain

15 to 30 minutes

May be facilitated by gently massaging abdomen or changing position

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis

Systems

• •

Automated peritoneal dialysis (APD)

Cycler delivers the dialysate

Times and controls fill, dwell, and drain Continuous ambulatory peritoneal dialysis (CAPD)

Manual exchange

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis

Complications

• • • • •

Exit site infection Peritonitis Abdominal pain Outflow problems Hernias

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis Complications (Cont’d)

• • • •

Lower back problems Bleeding Pulmonary complications Protein loss

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis Complications (Cont’d)

• • •

Carbohydrate and lipid abnormalities Encapsulating sclerosing peritonitis Loss of ultrafiltration

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Peritoneal Dialysis

Effectiveness and Adaptation

• • • • •

Short training program Independence Ease of traveling Fewer dietary restrictions Greater mobility than with HD

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Hemodialysis

Vascular Access Sites

Obtaining vascular access is one of most difficult problems

Types of access include

• • •

Shunts Internal arteriovenous fistulas and grafts Temporary vascular access

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Vascular Access for Hemodialysis

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-13

Hemodialysis

Dialyzers

• •

Long plastic cartridge that contains thousands of parallel hollow tubes or fibers Fibers are the semipermeable membrane

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Hemodialysis System

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-16

Hemodialysis

Procedure

• • •

Two needles placed in fistula or graft Needle closer to fistula or red catheter lumen pulls blood from patient and sends to dialyzer Blood returned from dialyzer to patient through second needle or blue catheter

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Hemodialysis

Procedure (Cont’d)

• • • •

Dialyzer/blood lines primed with saline solution to eliminate air Heparin added to blood as it flows to dialyzer Terminated by flushing dialyzer with saline to remove all blood Needles removed and firm pressure applied

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Hemodialysis

Procedure (Cont’d)

• •

Before treatment, nurse should

Complete assessment of fluid status, condition of access, temperature, skin condition During treatment, nurse should

Be alert to changes in condition

Perform vital signs every 30 to 60 minutes

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-17

Hemodialysis

Complications

• • • • • •

Hypotension Muscle cramps Loss of blood Hepatitis Sepsis Disequilibrium syndrome

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Hemodialysis

Effectiveness and Adaptation

• • •

Cannot fully replace metabolic and hormonal functions of kidneys Can ease many of the symptoms Can prevent certain complications

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT)

• • •

Alternative or adjunctive method for treating ARF Means by which uremic toxins and fluids are removed Acid-base status/electrolytes adjusted slowly and continuously

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

• • •

Can be used in conjunction with HD Contraindication

Presence of manifestations of uremia requiring rapid resolution Continued for 30 to 40 days

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

• • •

Hemofilter change every 24 to 48 hours Ultrafiltrate should be clear yellow Specimens may be obtained for evaluation

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

Two types of CRRT

Continuous arteriovenous therapies (CAVTs)

Continuous venovenous therapies (CVVTs)

Most commonly used

Continuous venovenous hemofiltration

(CVVH) Continuous venovenous hemodialysis (CVVHD)

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

Continuous venovenous hemofiltration (CVVH)

Large volume of fluid removed hourly,

then replaced Fluid replacement dependent on stability/individualized needs of patient

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

Continuous venovenous hemodialysis (CVVHD)

Uses dialysate

Dialysate bags attached to distal end of hemofilter

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

Continuous venovenous hemodialysis (CVVHD) (cont’d)

Fluid pumped countercurrent to blood

flow Ideal treatment for patient who needs fluid/solute control but cannot tolerate rapid fluid shifts with HD

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

• • •

Highly permeable, hollow fiber hemofilter Uses double-lumen catheter placed in femoral, jugular, or subclavian vein Removes plasma water and nonprotein solutes

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

CRRT versus HD

Continuous rather than intermittent

Solute removal by convection (no

dialysate required) in addition to osmosis and diffusion Less hemodynamic instability

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Continual Renal Replacement Therapy (CRRT) (Cont’d)

CRRT versus HD (cont’d)

Does not require constant monitoring by HD nurse

Does not require complicated HD equipment

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Fig. 47-19

Chronic Kidney Disease

Gerontologic Considerations

• •

About 35% of ESRD patients are 65 years of age or older Most common diseases leading to renal failure in the older adult

Hypertension

Diabetes

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Nursing Management

Evaluation

• • • • •

Maintenance of ideal body weight Acceptance of chronic disease No infections No edema Hematocrit, hemoglobin, and serum albumin levels in acceptable range

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Case Study

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Case Study

65-year-old female with history of progressive renal failure for 5 years

Diagnosed with type 1 diabetes mellitus when 15 years of age

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Case Study (Cont’d)

She has diabetic retinopathy with macular degeneration

Gives herself insulin using an insulin pen

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Case Study (Cont’d)

Lab values

BUN 72 mg/dl

Serum creatinine 7.5 mg/dl

GFR 12 ml/min

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.

Discussion Questions 1.

What are her options for renal replacement therapy?

2.

Which one would be the best choice for her?

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved.